Shanghai Henlius Biotech, Inc. Class H 2696

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.

Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.

Stocks closed out a choppy week on the back foot, with the Dow shedding nearly 2% and small caps underperforming as the Russell 2000 fell more than 1% on the week. The 10-year Treasury yield ticked up 6 basis points even as the VIX stayed contained near 17. Against that backdrop, a wave of earnings reports landed, giving traders fresh evidence on how margins and demand are holding up heading into the final quarter. Active Companies from around the markets with current developments this week incl

GE HealthCare Technologies has seen its share price slide this year, which naturally pushes investors to ask whether the current valuation still lines up with what the business is earning. With the stock drifting lower, the key question is how much of that move reflects a reset in expectations for its earnings power rather than just market sentiment. The share price is down 21.1% year to date, which puts the focus firmly on whether that drop now matches the earnings profile of GE...

Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core issue is how that performance and pipeline story stack up against what the business is actually generating in revenue. Takeda shares are up 120.5% over 5 years, which raises the question of how much of that gain is supported by the company’s sales...

Corteva (CTVA) said Thursday that a federal court in California denied its request to temporarily bl

Nexalin Technology (NXL) signed an agreement to appoint Inovanexa Medical Technologies as its exclus

Humana already told investors in July how many members it plans to drop. What your neighbor with a surviving plan has not figured out yet is how quietly the costs on that plan changed before open enrollment closes Dec. 7.

Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

Daiichi Sankyo Company has seen its share price fall over the past few years, so the key issue now is whether the current market value lines up with the cash the business is expected to generate. With investors also weighing fresh data around its cancer portfolio, the question is how much of that potential is already reflected in the price you see today. Over the past 3 years the stock has declined 27.6%, which puts the focus squarely on whether the underlying cash flows still support...

Pfizer (NYSE:PFE) reported positive Phase 2 results for tilrekimig in moderate to severe atopic dermatitis, meeting its main efficacy goal. The trispecific antibody targets multiple cytokines linked to type 2 inflammation, aiming to address both skin and airway disease biology. Pfizer plans Phase 3 trials of tilrekimig in atopic dermatitis and asthma, expanding its late stage immunology portfolio. These Phase 2 tilrekimig results and the move into Phase 3 are worth weighing against the rest...

U.S. District Judge Richard G. Andrews of the District of Delaware found on Wednesday that Liquidia induces infringement of claims 1 and 14 of United Therapeutics’ U.S. Patent No. 11,826,327.

Major shareholder announcement Reference is made to the press release issued by Coloplast A/S on 4 September 2026 regarding the expected implementation of the generational change in the ultimate ownership of Coloplast A/S. Coloplast A/S hereby announces that on 1 October 2026, Coloplast A/S has received the following major shareholder notification: NPLH Holding ApS, a company 100% owned and controlled by Niels Peter Louis-Hansen, has transferred, by way of a gift, all its shares in Coloplast Hol

TempraMed Technologies (VIVI.CN) closed its non-brokered private placement offering of unsecured con

Intuitive Surgical is beating estimates and raising margins while its installed base keeps expanding. Abbott is executing steadily across a diversified portfolio but growing at a more measured pace.

Tour featured Science Delivers interactive stations to celebrate impact science has on our everyday lives Bayer and Luke Bryan Brought #HerestotheFarmer to Fall 2026 Farm Tour with New FFA Challenge Tour featured Science Delivers interactive stations to celebrate impact science has on our everyday lives NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Five-time Entertainer of the Year Luke Bryan headlined his 17th Farm Tour in 2026 with Bayer returning as the presenting sponsor. After Luke brought th

Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.

Turning a monthly paycheck into permanent investment income sounds straightforward until you realize how dramatically the required capital swings based on one variable most people overlook when building their retirement portfolio.